Armoiry, XavierSpäth, Hans-MartinHenaine , Anna-MariaDussart, ClaudeCounsell, CarlConnock, Martin2021-12-242021-12-242021-06-03Armoiry, X, Späth, H-M, Henaine , A-M, Dussart, C, Counsell, C & Connock, M 2021, 'Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England : a review comparing the assessment by HAS and NICE', Expert opinion on biological therapy, vol. 21, no. 6, pp. 741-747. https://doi.org/10.1080/14712598.2021.18653051744-7682Jisc: fa87f0d62ae5462cbdd3e23ad77c1218ORCID: /0000-0001-6622-7839/work/164505653https://hdl.handle.net/2164/177747236337engprimary progressive multiple sclerosisOcrelizumabNICEHASHealth technology assessmentEnglandFrancehealth technology assessmentenglandocrelizumabfrancehasR MedicineDrug DiscoveryClinical BiochemistryPharmacologyRJournal item10.1080/14712598.2021.1865305http://www.scopus.com/inward/record.url?scp=85098540547&partnerID=8YFLogxK216